SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-065465
Filing Date
2021-03-02
Accepted
2021-03-02 16:01:59
Documents
14
Period of Report
2021-02-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d271841d8k.htm   iXBRL 8-K 32268
2 EX-10.1 d271841dex101.htm EX-10.1 78572
6 GRAPHIC g271841g0302204842834.jpg GRAPHIC 4536
  Complete submission text file 0001193125-21-065465.txt   267301

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ziop-20210224.xsd EX-101.SCH 3068
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ziop-20210224_lab.xml EX-101.LAB 18906
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ziop-20210224_pre.xml EX-101.PRE 11861
7 EXTRACTED XBRL INSTANCE DOCUMENT d271841d8k_htm.xml XML 3539
Mailing Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129
Business Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129 617-259-1970
ZIOPHARM ONCOLOGY INC (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 21703431
SIC: 2834 Pharmaceutical Preparations